Key result
Recombinant VSV GP-VP1 vaccine increases FMDV antibody levels in pigs compared to commercial vaccines.
Why the study?
Foot-and-mouth disease is highly contagious, and a study was conducted to overcome the drawbacks of the currently used inactivated vaccine.
Does a recombinant protein carrying FMDV VP1 GH loop epitope linked to VSV glycoprotein improve antibody response in field pigs compared to commercial vaccine?
Does a recombinant protein carrying FMDV VP1 GH loop epitope linked to VSV glycoprotein improve antibody response in field pigs compared to commercial vaccine?
A novel recombinant protein vaccine for foot-and-mouth disease showed superior immunogenicity to the current commercial vaccine in field pigs, offering a potentially safer and easier production method.
Answers are grounded in this paper and cite their sources.
Novel FMD recombinant antigen shows ELISA reactivity; leaves open protective efficacy and field utility pending in vivo trials.
Foot-and-mouth disease (FMD) is one of the most highly contagious animal diseases. In an effort to overcome the drawbacks of the currently used inactivated foot-and-mouth disease virus vaccine, a novel recombinant protein carrying foot-and-mouth disease virus VP1 GH loop epitope linked to vesicular stomatitis virus glycoprotein was expressed in a baculovirus system. Its antigenicity was confirmed with ELISA using monoclonal antibody against foot-and-mouth disease virus. Twice immunizations one month apart in field pigs resulted in a significant antibody increase compared to the glutathione S-transferase carrier containing the same epitope and the commercial vaccine. To my knowledge, this is the first report that the recombinant protein vaccine was superior to the current vaccine. Although further studies are required to examine their immunogenicity in a large number of animals, this study sheds light on the development of a novel recombinant protein vaccine that could be easily produced in a general laboratory as an alternative to the current FMD vaccine, which requires a biosafety level 3 containment facility for vaccine production.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) studied Foot-and-mouth disease (n=16). Recombinant vesicular stomatitis virus glycoprotein carrying FMDV type O VP1 GH loop epitope (VSV GP-VP1) vs. Glutathione S-transferase carrier (GST-VP1) and commercial inactivated FMDV vaccine was evaluated on Antibody response measured by FMDV type O ELISA (percentage inhibition) (p=<0.05). Immunization with the recombinant VSV GP-VP1 vaccine significantly increased FMDV antibody levels in field pigs compared to pre-immunization (P<0.05), whereas the GST carrier and commercial vaccine did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: